Salt Lake City, UT, June 4, 2019 – LifeVantage (Nasdaq:LFVN) has opened for business in Belgium, marking the company’s third European market launch in as many months.
“Our expansion strategy in Europe has been deliberate and aggressive, particularly this calendar year,” said LifeVantage CEO Darren Jensen. “It’s indicative of the traction the LifeVantage biohacking movement continues to gain in that part of the world, and we’re thrilled to now officially count the people of Belgium among our growing biohacking community.”
Select LifeVantage products have been offered in Belgium on a not-for-resale basis for approximately a year as part of the company’s Global Customer Acquisition Program. During that time, the country demonstrated consistent growth as a customer market, paving the way for the company to now open for distributor enrollments as well. It’s a blueprint that has helped drive much of the company’s recent growth and expansion in Europe.
“As a company, this model has allowed us to build a presence and customer base throughout Europe, which, in turn, is enabling current and new distributors to really hit the ground running in these respective European countries as they open,” said LifeVantage Chief Sales Officer Justin Rose.
LifeVantage opened in Austria in September, Spain in March, and Ireland in May.
The company has been in neighboring Netherlands since 2016 and also has a long-standing presence in the United Kingdom and Germany.
Products now available in Belgium include the company’s flagship Protandim Nrf2 Synergizer® supplement, Protandim Nrf1 Synergizer® supplement – which was just made available in parts of Europe for the first time this month – Omega+ fish oil supplement, Pro+ (as it’s known in Europe) probiotic supplement, TrueScience® Facial Cleanser, TrueScience® Perfecting Lotion, TrueScience® Eye Serum, TrueScience® Anti-Aging Cream, and TrueScience® Hand Cream.
With the addition of Belgium, LifeVantage now serves 15 markets in North America, Europe, Australia, and Asia.
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics – a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development, and distribution of advanced nutrigenomic dietary supplements and skin and hair care products, including its scientifically-validated
Protandim® product line, Omega+ and ProBio dietary supplements, its TrueScience® line of Nrf2-infused skin and hair care products, PetandimTM for Dogs, Axio® Smart Energy Drink mixes, and the PhysIQTM Smart Weight Management System. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”, “anticipates”, “look forward to”, “goal”, “may be”, and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future growth, projected success in certain markets, distributor success, and shareholder value. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.